BBIO Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 days ago - By: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

9 days ago - By: Benzinga - Mentions: VRTX AZN HUM UNH ...

10 Health Care Stocks With Whale Alerts In Today's Session

15 days ago - By: BridgeBio Pharma, Inc.

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

25 days ago - By: Benzinga - Mentions: CGO ROL ESRT NNBR ...

Earnings Scheduled For October 29, 2025

25 days ago - By: Investor's Business Daily

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High

15 days ago - By: BridgeBio Pharma, Inc.

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

19 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Participate in November Investor Conferences

19 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Participate in November Investor Conferences

20 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

20 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

24 days ago - By: Investor's Business Daily - Mentions: PFE ALNY IONS AZN

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

24 days ago - By: Zacks Investment Research - Mentions: SUPN

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

24 days ago - By: BridgeBio Pharma, Inc.

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

24 days ago - By: BridgeBio Pharma, Inc.

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

24 days ago - By: Stocktwits - Mentions: VFMO EAOR

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results

25 days ago - By: BridgeBio Pharma, Inc.

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

25 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

25 days ago - By: BridgeBio Pharma, Inc.

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

a month ago - By: Stocktwits - Mentions: UWM VTWG

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

a month ago - By: Bloomberg

BridgeBio’s Drug for Muscle Disorder Meets Goal in Key Trial

a month ago - By: BridgeBio Pharma, Inc.

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

a month ago - By: BridgeBio Pharma, Inc.

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

a month ago - By: BridgeBio Pharma, Inc.

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

a month ago - By: BridgeBio Pharma, Inc.

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

2 months ago - By: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: BridgeBio Pharma, Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: ALNY NVS PFE

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

2 months ago - By: Investor's Business Daily - Mentions: PFE

BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival

2 months ago - By: BridgeBio Pharma, Inc.

BRIDGEBIO PHARMA INC (BBIO) Stock News

BBIO Latest News, Press Relases and Analysis

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 Health Care Stocks With Whale Alerts In Today's Session

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Earnings Scheduled For October 29, 2025

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

BridgeBio to Participate in November Investor Conferences

BridgeBio to Participate in November Investor Conferences

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

BridgeBio’s Drug for Muscle Disorder Meets Goal in Key Trial

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM